Very are delighted to announce that our CEO Eric Halioua will chair a panel April 28th at the 5th Neoantigen Summit Europe organized by Hanso Wade in Amsterdam, Netherlands from April 26th to April...
We are delighted to announce of the publication by our CSO Joël Plumas of a new review article in scientific journal Current Opinion in Oncology and intitled "Harnessing dendritic cells for innovative...
PDC*line Pharma raises €17.5 million ($20,3M) in Series B2 financing round
New funding includes €11.8M in equity and €5.7M in grants. It completes the €20M B1 round of financing announced in January...
B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed
...
It has been a pleasure and an honor for our CEO Eric Halioua to participate Friday October 8th as a speaker at the EU-Korea Global Vaccine partnership roundtable with Mr Han-koo Yeo, Minister for...
Available now for replay, the interview of PDC*line Pharma 's President & CEO Eric Halioua by journalist of the program « Itinéraires santé » in the TV studio of the French Media group Le Figaro.
In...
In replay, the intervention of our CEO Eric Halioua and one of our investors Marc Foidart of the Noshaq fund on Monday May 17th at the "Success stories" program dedicated to the Biotechnology on the...
PDC*line Pharma CEO Eric Halioua and COO/CFO Laurent Levy will be present at the Bio€quity Europe 2021 conference Delivered Digitally May 17 - 19, 2021
! A company presentation made by our CEO on our...
We are very pleased to announce that our abstract describing our current phase I/II clinical trial objectives and design with our cancer vaccine PDC*lung01 has been accepted for presentation at the...
